Copertina

Impact of naturally occurring polymorphisms on the structure of HIV-1 integrase that can influence dolutegravir binding among subtypes A1 and D.

Fuente: Zenodo

Salvato in:

Dettagli Bibliografici
Autore principale:	Ssekagiri, Alfred
Natura:	Recurso digital
Pubblicazione:	Zenodo 2026
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A nanoemulsified formulation of dolutegravir and epigallocatechin gallate inhibits HIV‐1 replication in cellular models
di: Shraddha Y. Gaikwad, et al.
Pubblicazione: (2024)

Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
di: C. Hu, et al.
Pubblicazione: (2025)

Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed
di: C. Piñeiro, et al.
Pubblicazione: (2024)

Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use
di: Kathleen J. Pincus, et al.
Pubblicazione: (2025)

Therapeutic drug monitoring of dolutegravir in children and adolescents living with HIV: A retrospective study
di: E. Pilote, et al.
Pubblicazione: (2025)

Simplifying explicit subtyping coercions in a polymorphic calculus with effects
di: Koprivec, Filip, et al.
Pubblicazione: (2024)

A preliminary analysis of the impact of pharmacogenetic variation on bictegravir and dolutegravir concentrations in individuals with HIV and tuberculosis
di: A. Naidoo, et al.
Pubblicazione: (2025)

Rethinking HIV treatment: How non‐integrase strand regimens may hold the key to better immune health
di: Bogusz Aksak‐Wąs, et al.
Pubblicazione: (2025)

Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
di: Thierry Tiendrebeogo, et al.
Pubblicazione: (2024)

High peak viraemia followed by spontaneous HIV‐1 control in women living with HIV‐1 subtype A1 in East Africa
di: Yifan Li, et al.
Pubblicazione: (2025)

Impact of HBV serological status on HIV virological efficacy of two‐drug antiretroviral regimens: A retrospective observational study on virologically suppressed people with HIV switching to lamivudine/dolutegravir
di: Pierluigi Francesco Salvo, et al.
Pubblicazione: (2025)

Effectiveness and tolerability of dolutegravir/lamivudine in virologically suppressed people with HIV at 96 weeks in a multicentre cohort
di: Inés Suárez‐García, et al.
Pubblicazione: (2025)

Blood pressure and metabolic outcomes after efavirenz‐ or dolutegravir‐based therapy started in acute HIV infection
di: Phillip Chan, et al.
Pubblicazione: (2025)

Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná
di: Bárbara Thaís Poliselo de Sá
Pubblicazione: (2022)

Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
di: C. Hu, et al.
Pubblicazione: (2025)

Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study
di: Axel Ursenbach, et al.
Pubblicazione: (2024)

Clinical outcomes of switching to dolutegravir/lamivudine dual therapy in people living with HIV: A single‐centre retrospective study
di: D. Yagci‐Caglayik, et al.
Pubblicazione: (2025)

The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens
di: Baralee Punyawudho, et al.
Pubblicazione: (2024)

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
di: Santiago Moreno Guillén
Pubblicazione: (2017)

Novel diarylpyrimidine subtypes as HIV‐1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile
di: Zhengqiang Wang
Pubblicazione: (2024)

No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people withHIV with profound immunosuppression
di: Chi Kuen Chan, et al.
Pubblicazione: (2024)

APOL1 polymorphisms are not influencing acute coronary syndrome risk in Czech males
di: Jaroslav A. Hubacek, et al.
Pubblicazione: (2024)

“Editorial comment on: Increased incidence of diabetes in people living with HIV treated with first‐line integrase strand transfer inhibitors: A French multicentre retrospective study”
di: Félix Gutiérrez
Pubblicazione: (2024)

Improvements in cognitive performance switching from efavirenz‐ to dolutegravir‐based antiretroviral therapy in South African people with HIV: the CONNECT study
di: Sam Nightingale
Pubblicazione: (2025)

The influence of the Casimir effect on the binding potential for 3D wetting
di: Squarcini, Alessio, et al.
Pubblicazione: (2025)

Genetic polymorphisms influencing antihypertensive drug responses
di: Jana El Cheikh, et al.
Pubblicazione: (2024)

How can embedding models bind concepts?
di: Uselis, Arnas, et al.
Pubblicazione: (2026)

Jacquetium: a new, naturally-occurring chemical element
di: Jacquet, Emmanuel
Pubblicazione: (2025)

Unveiling the influence of crystal structure polymorphs on radiation shielding properties: A case study of SiO 2
di: Ziad Khattari
Pubblicazione: (2024)

The ber pathway genes and pon1 polymorphism: influence on dna damage in agriculture-exposed workers
di: Paula Rohr
Pubblicazione: (2006)

Correction to “Genetic polymorphisms influencing antihypertensive drug responses”
Pubblicazione: (2025)

Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin‐based regimen: A retrospective observational case series
di: Yanyun Dou, et al.
Pubblicazione: (2024)

Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes
di: Anta L, et al.
Pubblicazione: (2025)

Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients
di: Tom G. Jacobs, et al.
Pubblicazione: (2024)

Characteristics and influencing factors of anticipated HIV stigma among HIV‐negative/unknown MSM in China: A regression mixture model
di: Zhenwei Dai, et al.
Pubblicazione: (2024)

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV : Data from the COMBINE ‐2 study
di: Cristina Mussini, et al.
Pubblicazione: (2026)

Diagnosis of naturally occurring canine hypercortisolism: survey of Australian veterinarians
di: MA Wray, et al.
Pubblicazione: (2025)

Electrophoretic assembly of naturally occurring humic substances as thin films
Pubblicazione: (2003)

Trends in the electronic structure of borophene polymorphs
di: Osorio, Alam, et al.
Pubblicazione: (2025)

Paraconsistents artificial neural networks applied to the study of mutational patterns of the F subtype of the viral strains of HIV-1 to antiretroviral therapy
di: PAULO C.C. DOS SANTOS
Pubblicazione: (2016)